bs-20379R [Primary Antibody]
TLR4 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: TLR4

Immunogen Range: 431-530/843


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 7099

Swiss Prot: O00206

Source: KLH conjugated synthetic peptide derived from human TLR4

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

The Toll-like receptor 4 by activating natural immunity, specific immune response involved in the start-up, Toll-like receptor 4 as an important signal transduction transmembrane receptor involved in the toxin-induced inflammation in the pathological process, its mechanisms of control On a growing concern. all regions were either double-stranded or sequenced with an alternatechemistry or covered by high quality data(i.e., phred quality >=30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by at least one subclone; and the assembly was confirmed by restriction digest, except on the rare occasion of the clone being a YAC. The following abbreviations are used to associate primary accession numbers given in the feature table with their source databases: Em:, EMBL; Sw:, SWISSPROT; Tr:, TREMBL; Wp:, WORMPEP; Information on the WORMPEP database can be found at. TLR-4 plays an important role in microvascular leakage and leukocyte adhesion under the inflammatory condition associated with nonseptic thermal injury.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)

Predicted Molecular Weight: 90


Cross Reactive Species: Human
Bovine

Predicted Cross Reactive Species: Horse
Chicken

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Lopez V et al. Comparative proteomics identified immune response proteins involved in response to vaccination with heat-inactivated Mycobacterium bovis and mycobacterial challenge in cattle. (2018) Vet. Immunol. Immunopathol. Dec;206:54-64. Read more>>
  • Jian Wang. et al. Lactobacillus salivarius ameliorated Mycoplasma gallisepticum-induced inflammatory injury and secondary Escherichia coli infection in chickens: Involvement of intestinal microbiota. Vet Immunol Immunop. 2021 Mar;233:110192Read more>>
  • Jian Wang. et al. A respiratory commensal bacterium acts as a risk factor for Mycoplasma gallisepticum infection in chickens. Vet Immunol Immunop. 2020 Dec;230:110127Read more>>
  • Yusong Miao. et al. Methylsulfonylmethane ameliorates inflammation via NF-_B and ERK/JNK-MAPK signaling pathway in chicken trachea and HD11 cells during Mycoplasma gallisepticum infection. Poultry Sci. 2022 Jan;:101706Read more>>
  • Yusong Miao. et al. Mycoplasma gallisepticum induced inflammation-mediated Th1/Th2 immune imbalance via JAK/STAT signaling pathway in chicken trachea: Involvement of respiratory microbiota. Vet Microbiol. 2022 Feb;265:10933Read more>>
  • Zhao, Lei. et al. Lactobacillus plantarum S9 alleviates lipid profile, insulin resistance, and inflammation in high-fat diet-induced metabolic syndrome rats. SCI REP-UK. 2022 Sep;12(1):1-1Read more>>
  • Chen Bai. et al. Ac2?26 alleviates hepatic ischemia?reperfusion injury based on inhibiting the positive feedback loop of HMGB1/TLR4/NF?B/neutrophils. EXP THER MED. 2022 Nov;24(5):1-1Read more>>
  • Shanshan Shen. et al. Recombinant Antimicrobial Peptide OaBac5mini Alleviates Inflammation in Pullorum Disease Chicks by Modulating TLR4/MyD88/NF-κB Pathway. ANIMALS. 2023 Jan;13(9):1515Read more>>
  • Lemiao Zhong. et al. Mycoplasma synoviae induce spleen tissue damage and inflammatory response of chicken through oxidative stress and apoptosis. VIRULENCE. 2023 Nov 16Read more>>
VALIDATION IMAGES

HL60 lysates probed with TLR4 Polyclonal Antibody, Unconjugated (bs-20379R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.